in its ability to market its blood substitute technology for both animal and human use. Further‚ Biopure has the patents and FDA approval to forge ahead in the animal market with a two-to-five year time buffer from new competition (using similar technology). One of the company’s weaknesses is that it has not received FDA approval on Hemopure‚ and there are two other companies that could beat Biopure to the market with similar products. But if the FDA does not approve Hemopure‚ which could have
Premium Blood Pharmacology Marketing
Biopure Case Study Executive Summary * Biopure Corporation developed two new products to enter into the field of blood substitutes: Hemopure‚ directed to the human market and Oxyglobin‚ for the veterinary market. Through the end of 1997 no blood substitute had received approval for use anywhere in the world. * What distinguishes both products from other “hemoglobin-based” blood substitutes is the fact that they are “bovine-sourced” as opposed to “human-sourced”‚ i.e. they are derived from
Free Blood Blood transfusion
Executive Summary Biopure Corporation was established in 1984 and is a privately owned pharmaceutical firm. They are trying to launch two new products: Hemopure (human market) and Oxyglobin (veterinary market). They are the only company aggressively engaged in the development of blood substitutes for the vet market. Biopure has invested $200M in the development of said blood substitutes. They currently don’t have any revenues with little to no debt and financing of $50M to support these operations
Premium Health care Net present value Medicine
+ Biopure Corporation Case Analysis Back Bay Xue Yang + Agenda 1. Current Situation 2. SWOT Analysis 3. Quantitative Analysis 4. Recommendations + Current SituationBiopure Corporation The main objectives of Biopure Corporation is blood substitutes development There are 2 products: Oxyglobin and Hemopure. Oxyglobin is targeting at veterinary market and Hemopure is targeting at human market The company has spent $200 million on R&D of Hemopure Oxyglobin has already approved
Premium Variable cost Blood Marketing
the FDA. Besides the financial benefit of having stable revenues during the approval process‚ the company would start to build a brand awareness and reputation that will later benefit the marketing and sales of Hemopure. Additionally‚ launching Oxyglobin will protect the veterinary market from entrants like Baxter or Northfield that could decide to sell veterinary products while waiting for the FDA
Premium Blood Organ transplant Blood transfusion
I: Analysis Oxyglobin’s Immediate Launch It is our recommendation that Biopure should immediately launch Oxyglobin. The reasons for this decision are as followed: Obtaining the Monopoly on blood substitutes - If Biopure waits to launch Oxyglobin they will miss a prime opportunity to control the blood substitute market‚ especially the animal market. As mentioned in the case‚ Biopure’s competitors have yet to launch their products. Furthermore‚ Baxter International and Northfield Laboratories do
Premium Blood transfusion Blood Marketing
Biopure Case Analysis Group 1‚ Section B The analysis deals with the Target Markets and their different segments for the two products of Biopure Corporation‚ namely Oxyglobin and Hemopure. Oxyglobin -‐ Used as a substitute for blood transfusion in dogs. -‐ Target market is 30% of all the
Premium
Executive Summary Biopure Corporation is one of the pioneers in the development of oxygen therapeutics using “Hemoglobin”‚ a new class of pharmaceuticals that deliver oxygen to the body’s tissues. Biopure developed two main products under years of research and development‚ “Hemopure” for human use‚ and “Oxyglobin” for animal veterinary use‚ both represented a new oxygen based treatment approach for managing patients’ oxygen requirements. Biopure’s two products differ from other blood substitute
Free Blood Blood transfusion
Biopure Market Potential Exercise Suggested Solution Question 1) How would you revise the market potential for Hemopure? The best four-segment solution to the usage problem includes these categories: elective surgery; emergency surgery; in field trauma; and chronic anemia. Current Usage Change Potential Usage Trauma (in field) 200‚000 *10 2‚000‚000 Currently only 10% of trauma cases get blood transfusions in the field. With better storage potential and no need for blood
Free Blood Blood transfusion Surgery
* Students launch Malaysia’s first weather balloon to Near Space * On 17th of March a group of high school students launch a weather balloon to up to 80‚000feet in the stratosphere to capture a glimpse of earth from near space. The launch is believed to be first of its kind in Malaysia. * This group consist of 8 passionate students from Hin Hua High School‚ they launched a weather balloon equipped with gps navigating systems & a digital camera to stratosphere at Sabak Bernam on
Premium Wind Camera Meteorology